These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
783 related articles for article (PubMed ID: 36047968)
1. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors. Adachi K; Tamada K Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968 [TBL] [Abstract][Full Text] [Related]
2. [Development of CAR-T Cells Effective against Solid Tumors]. Adachi K; Tamada K Gan To Kagaku Ryoho; 2023 May; 50(5):577-583. PubMed ID: 37218315 [TBL] [Abstract][Full Text] [Related]
3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
4. Novel technologies for improving the safety and efficacy of CAR-T cell therapy. Ohta K; Sakoda Y; Tamada K Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630 [TBL] [Abstract][Full Text] [Related]
5. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830 [TBL] [Abstract][Full Text] [Related]
6. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations. Brookens SK; Posey AD Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155 [TBL] [Abstract][Full Text] [Related]
8. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. Qin Y; Xu G Front Immunol; 2022; 13():1053120. PubMed ID: 36569859 [TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances. Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567 [TBL] [Abstract][Full Text] [Related]
10. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. Guedan S; Alemany R Front Immunol; 2018; 9():2460. PubMed ID: 30405639 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524 [TBL] [Abstract][Full Text] [Related]
13. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors. Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900 [TBL] [Abstract][Full Text] [Related]
14. Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. Cherkassky L; Hou Z; Amador-Molina A; Adusumilli PS Cancer Cell; 2022 Jun; 40(6):569-574. PubMed ID: 35487216 [TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208 [TBL] [Abstract][Full Text] [Related]
16. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Sloas C; Gill S; Klichinsky M Front Immunol; 2021; 12():783305. PubMed ID: 34899748 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y Front Immunol; 2022; 13():871661. PubMed ID: 35911706 [TBL] [Abstract][Full Text] [Related]
18. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies. Wang H; Pan W Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614 [TBL] [Abstract][Full Text] [Related]
19. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557 [TBL] [Abstract][Full Text] [Related]
20. How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors? Schoenfeld AJ; O'Cearbhaill RE Cancer J; 2021 Mar-Apr 01; 27(2):134-142. PubMed ID: 33750073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]